FILE 'HOME' ENTERED AT 15:33:03 ON 28 AUG 2003

=> file bioscience
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'ADISCTI' ENTERED AT 15:33:15 ON 28 AUG 2003
COPYRIGHT (C) 2003 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 15:33:15 ON 28 AUG 2003
COPYRIGHT (C) 2003 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 15:33:15 ON 28 AUG 2003
COPYRIGHT (C) 2003 Adis Data Information BV

FILE 'AGRICOLA' ENTERED AT 15:33:15 ON 28 AUG 2003

FILE 'ANABSTR' ENTERED AT 15:33:15 ON 28 AUG 2003
COPYRIGHT (c) 2003 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'AQUASCI' ENTERED AT 15:33:15 ON 28 AUG 2003
COPYRIGHT 2003 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 15:33:15 ON 28 AUG 2003
COPYRIGHT (C) 2003 Biological Abstracts, Inc. (BIOSIS)

FILE 'BIOCOMMERCE' ENTERED AT 15:33:15 ON 28 AUG 2003
COPYRIGHT (C) 2003 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All rights reserved

FILE 'BIOSIS' ENTERED AT 15:33:15 ON 28 AUG 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 15:33:15 ON 28 AUG 2003
COPYRIGHT (C) 2003 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'BIOTECHNO' ENTERED AT 15:33:15 ON 28 AUG 2003
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 15:33:15 ON 28 AUG 2003
COPYRIGHT (C) 2003 CAB INTERNATIONAL (CABI)

FILE 'CANCERLIT' ENTERED AT 15:33:15 ON 28 AUG 2003

FILE 'CAPLUS' ENTERED AT 15:33:15 ON 28 AUG 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB' ENTERED AT 15:33:15 ON 28 AUG 2003
COPYRIGHT (c) 2003 DECHEMA eV

FILE 'CEN' ENTERED AT 15:33:15 ON 28 AUG 2003
COPYRIGHT (C) 2003 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 15:33:15 ON 28 AUG 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 15:33:15 ON 28 AUG 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'CROPB' ENTERED AT 15:33:15 ON 28 AUG 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'CROPU' ENTERED AT 15:33:15 ON 28 AUG 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'DDFB' ACCESS NOT AUTHORIZED

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 15:33:15 ON 28 AUG 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'DRUGB' ENTERED AT 15:33:15 ON 28 AUG 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'DRUGLAUNCH' ENTERED AT 15:33:15 ON 28 AUG 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'DRUGMONOG2' ENTERED AT 15:33:15 ON 28 AUG 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'DRUGNL' ENTERED AT 15:33:15 ON 28 AUG 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 15:33:15 ON 28 AUG 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'DRUGUPDATES' ENTERED AT 15:33:15 ON 28 AUG 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'EMBAL' ENTERED AT 15:33:15 ON 28 AUG 2003
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'EMBASE' ENTERED AT 15:33:15 ON 28 AUG 2003
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 15:33:15 ON 28 AUG 2003
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FEDRIP' ENTERED AT 15:33:15 ON 28 AUG 2003

FILE 'FOMAD' ENTERED AT 15:33:15 ON 28 AUG 2003
COPYRIGHT (C) 2003 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 15:33:15 ON 28 AUG 2003
COPYRIGHT (C) 2003 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 15:33:15 ON 28 AUG 2003
COPYRIGHT (C) 2003 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 15:33:15 ON 28 AUG 2003
COPYRIGHT (C) 2003 International Food Information Service

FILE 'GENBANK' ENTERED AT 15:33:15 ON 28 AUG 2003

FILE 'HEALSAFE' ENTERED AT 15:33:15 ON 28 AUG 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 15:33:15 ON 28 AUG 2003
COPYRIGHT (C) 2003 IFI CLAIMS(R) Patent Services (IFI)

FILE 'JICST-EPLUS' ENTERED AT 15:33:15 ON 28 AUG 2003
COPYRIGHT (C) 2003 Japan Science and Technology Corporation (JST)

FILE 'KOSMET' ENTERED AT 15:33:15 ON 28 AUG 2003
COPYRIGHT (C) 2003 International Federation of the Societies of Cosmetics Chemists

FILE 'LIFESCI' ENTERED AT 15:33:15 ON 28 AUG 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 15:33:15 ON 28 AUG 2003
COPYRIGHT (c) 2003 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 15:33:15 ON 28 AUG 2003

FILE 'NIOSHTIC' ENTERED AT 15:33:15 ON 28 AUG 2003
COPYRIGHT (C) 2003 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 15:33:15 ON 28 AUG 2003
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2003)

FILE 'NUTRACEUT' ENTERED AT 15:33:15 ON 28 AUG 2003
Copyright 2003 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'OCEAN' ENTERED AT 15:33:15 ON 28 AUG 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 15:33:15 ON 28 AUG 2003
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2003 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 15:33:15 ON 28 AUG 2003
COPYRIGHT (C) 2003 WIPO

FILE 'PHAR' ENTERED AT 15:33:15 ON 28 AUG 2003
COPYRIGHT (C) 2003 PJB Publications Ltd. (PJB)

FILE 'PHARMAML' ENTERED AT 15:33:15 ON 28 AUG 2003
Copyright 2003 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 15:33:15 ON 28 AUG 2003
COPYRIGHT (C) 2003 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 15:33:15 ON 28 AUG 2003
COPYRIGHT (C) 2003 PJB Publications Ltd. (PJB)

FILE 'PROMT' ENTERED AT 15:33:15 ON 28 AUG 2003
COPYRIGHT (C) 2003 Gale Group. All rights reserved.

FILE 'RDISCLOSURE' ENTERED AT 15:33:15 ON 28 AUG 2003
COPYRIGHT (C) 2003 Kenneth Mason Publications Ltd.

FILE 'SCISEARCH' ENTERED AT 15:33:15 ON 28 AUG 2003
COPYRIGHT 2003 THOMSON ISI

FILE 'SYNTHLINE' ENTERED AT 15:33:15 ON 28 AUG 2003
COPYRIGHT (C) 2003 Prous Science

FILE 'TOXCENTER' ENTERED AT 15:33:15 ON 28 AUG 2003
COPYRIGHT (C) 2003 ACS

FILE 'USPATFULL' ENTERED AT 15:33:15 ON 28 AUG 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

```
FILE 'USPAT2' ENTERED AT 15:33:15 ON 28 AUG 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 15:33:15 ON 28 AUG 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'VETU' ENTERED AT 15:33:15 ON 28 AUG 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'WPIDS' ENTERED AT 15:33:15 ON 28 AUG 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> s (lipi? (s) (glycopeptide or saccharide#) (s) antibiotic?) and (pharmaceutic? (s)
composition#)
SACCHARIDE#) IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s (lipi? (s) (glycopeptide or saccharide) (s) antibiotic?) and (pharmaceutic? (s)
composition)
L1            0 FILE ADISCTI
L2            0 FILE ADISINSIGHT
L3            0 FILE ADISNEWS
L4            0 FILE AGRICOLA
L5            0 FILE ANABSTR
L6            0 FILE AQUASCI
L7            0 FILE BIOBUSINESS
L8            0 FILE BIOCOMMERCE
L9            0 FILE BIOSIS
L10           0 FILE BIOTECHDS
L11           0 FILE BIOTECHNO
L12           0 FILE CABA
L13           0 FILE CANCERLIT
L14           0 FILE CAPLUS
L15           0 FILE CEABA-VTB
L16           0 FILE CEN
L17           0 FILE CIN
L18           0 FILE CONFSCI
L19           0 FILE CROPB
L20           0 FILE CROPU
L21           0 FILE DGENE
L22           0 FILE DRUGB
L23           0 FILE DRUGLAUNCH
L24           0 FILE DRUGMONOG2
L25           0 FILE DRUGNL
L26           0 FILE DRUGU
L27           0 FILE DRUGUPDATES
L28           0 FILE EMBAL
L29           0 FILE EMBASE
L30           0 FILE ESBIOBASE
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'LIPI? (S) '
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'CCHARIDE) (S) ANTIBIOTI'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'MACEUTIC? (S) COMPOSITI'
L31           0 FILE FEDRIP
L32           0 FILE FOMAD
L33           0 FILE FOREGE
L34           0 FILE FROSTI
L35           0 FILE FSTA
L36           0 FILE GENBANK
```

```
L37           0 FILE HEALSAFE
L38           1 FILE IFIPAT
L39           0 FILE JICST-EPLUS
L40           0 FILE KOSMET
L41           0 FILE LIFESCI
L42           0 FILE MEDICONF
L43           0 FILE MEDLINE
L44           0 FILE NIOSHTIC
L45           0 FILE NTIS
L46           0 FILE NUTRACEUT
L47           0 FILE OCEAN
L48           0 FILE PASCAL
L49           0 FILE PCTGEN
L50           0 FILE PHAR
L51           0 FILE PHARMAML
L52           0 FILE PHIC
L53           0 FILE PHIN
L54           0 FILE PROMT
L55           1 FILE RDISCLOSURE
L56           0 FILE SCISEARCH
L57           0 FILE SYNTHLINE
L58           0 FILE TOXCENTER
L59          21 FILE USPATFULL
L60           0 FILE USPAT2
L61           0 FILE VETB
L62           0 FILE VETU
L63           5 FILE WPIDS

TOTAL FOR ALL FILES
L64          28 (LIPI? (S) (GLYCOPEPTIDE OR SACCHARIDE) (S) ANTIBIOTIC?) AND
                (PHARMACEUTIC? (S) COMPOSITION)

=> dup rem l64
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE,
DRUGLAUNCH, DRUGMONOG2, DRUGUPDATES, FEDRIP, FOREGE, GENBANK, KOSMET,
MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, RDISCLOSURE, SYNTHLINE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L64
L65           27 DUP REM L64 (1 DUPLICATE REMOVED)

=> d l65 1-27 ibib abs

L65  ANSWER 1 OF 27  USPATFULL on STN
ACCESSION NUMBER:        2003:231998  USPATFULL
TITLE:                   Diagnosing genetic disorders
INVENTOR(S):             Rothschild, Kenneth J., Newton, MA, UNITED STATES
                         Sonar, Sanjay M., Boston, MA, UNITED STATES
                         Olejnik, Jerzy, Allston, MA, UNITED STATES
PATENT ASSIGNEE(S):      The Trustees of Boston University (U.S. corporation)

                              NUMBER        KIND    DATE
                         ---------------- ------ --------
PATENT INFORMATION:      US 2003162198      A1   20030828
APPLICATION INFO.:       US 2002-264126     A1   20021003  (10)
RELATED APPLN. INFO.:    Continuation of Ser. No. US 2000-504001, filed on 14
                         Feb 2000, PENDING Continuation of Ser. No. US
                         1995-479389, filed on 7 Jun 1995, GRANTED, Pat. No. US
                         6057096 Continuation of Ser. No. US 1994-345807, filed
                         on 22 Nov 1994, GRANTED, Pat. No. US 5986076
                         Continuation-in-part of Ser. No. US 1994-240511, filed
                         on 11 May 1994, GRANTED, Pat. No. US 5643722
DOCUMENT TYPE:           Utility
FILE SEGMENT:            APPLICATION
LEGAL REPRESENTATIVE:    MEDLEN & CARROLL, LLP, Suite 350, 101 Howard Street,
                         San Francisco, CA, 94105
NUMBER OF CLAIMS:        20
```

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 26 Drawing Page(s)
LINE COUNT: 3629
AB This invention relates to agents and conjugates that can be used to detect and isolate target components from complex mixtures such as nucleic acids from biological samples, cells from bodily fluids, and nascent proteins from translation reactions. Agents comprise a detectable moiety bound to a photoreactive moiety. Conjugates comprise agents coupled to substrates by covalent bounds which can be selectively cleaved with the administration of electromagnetic radiation. Targets substances labeled with detectable molecules can be easily identified and separated from a heterologous mixture of substances. Exposure of the conjugate to radiation releases the target in a functional form and completely unaltered. Using photocleavable molecular precursors as the conjugates, label can be incorporated into macromolecules, the nascent macromolecules isolated and the label completely removed. The invention also relates to targets isolated with these conjugates which may be useful as **pharmaceutical** agents or **compositions** that can be administered to humans and other mammals. Useful **compositions** include biological agents such as nucleic acids, proteins, lipids and cytokines. Conjugates can also be used to monitor the pathway and half-life of **pharmaceutical composition** in vivo and for diagnostic, therapeutic and prophylactic purposes. The invention also relates to kits comprised of agents and conjugates that can be used for the detection of diseases, disorders and nearly any individual substance in a complex background of substances.

L65 ANSWER 2 OF 27 USPATFULL on STN
ACCESSION NUMBER: 2003:188376 USPATFULL
TITLE: Methods of treating drug-resistant bacterial infections
INVENTOR(S): Hergenrother, Paul J., Champaign, IL, UNITED STATES
Musk, Dinty J., JR., Champaign, IL, UNITED STATES
DeNap, Johna C.B., Rantoul, IL, UNITED STATES
PATENT ASSIGNEE(S): The Board of Trustees of the University of Illinois (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003130169	A1	20030710	
APPLICATION INFO.:	US 2002-261851	A1	20021001	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2001-326315P	20011001	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SONNENSCHEIN NATH & ROSENTHAL, P.O. BOX 061080, WACKER DRIVE STATION, CHICAGO, IL, 60606-1080
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)
LINE COUNT: 1065
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods for treatment of antibiotic-resistant and multi-drug resistant bacterial infections are provided. The methods comprise administration of compositions which mimic plasmid incompatibility in bacteria, resulting in their sensitization to previously resistant drugs. Also provided herein are methods for screening compositions for the ability to mimic plasmid incompatibility by inhibiting Rep protein or by destabilizing RNA/RNA stem loop "kissing" structures. The invention also encompasses compositions identified by the screening methods disclosed herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L65 ANSWER 3 OF 27 USPATFULL on STN
ACCESSION NUMBER: 2003:152847 USPATFULL
TITLE: Betaines as adjuvants to susceptibility testing and antimicrobial therapy
INVENTOR(S): Thornton, Charles G., Damascus, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003104513	A1	20030605
APPLICATION INFO.:	US 2002-125647	A1	20020419 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1999-429614, filed on 29 Oct 1999, GRANTED, Pat. No. US 6406880
Continuation of Ser. No. WO 1998-US8760, filed on 1 May 1998, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-45512P	19970502 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STERNE, KESSLER, GOLDSTEIN & FOX PLLC, 1100 NEW YORK AVENUE, N.W., SUITE 600, WASHINGTON, DC, 20005-3934
NUMBER OF CLAIMS: 143
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 56 Drawing Page(s)
LINE COUNT: 4772
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is related to methods and compositions for susceptibility testing of bacteria containing mycolic acid structures using betaine-like detergents, and inducing the susceptibility of such bacteria using the same.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L65 ANSWER 4 OF 27 USPATFULL on STN
ACCESSION NUMBER: 2003:86990 USPATFULL
TITLE: Glycopeptide derivatives and **pharmaceutical compositions** containing the same
INVENTOR(S): Judice, J. Kevin, El Granada, CA, UNITED STATES
Fatheree, Paul Ross, San Francisco, CA, UNITED STATES
Lam, Bernice M.T., San Francisco, CA, UNITED STATES
Leadbetter, Michael R., San leandro, CA, UNITED STATES
Linsell, Martin S., San Mateo, CA, UNITED STATES
Mu, YongQi, Los Altos, CA, UNITED STATES
Trapp, Sean Gary, San Francisco, CA, UNITED STATES
Yang, Guang, San Mateo, CA, UNITED STATES
Zhu, Yan, Foster City, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003060598	A1	20030327
APPLICATION INFO.:	US 2002-92088	A1	20020306 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-470209, filed on 22 Dec 1999, GRANTED, Pat. No. US 6392012

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-113728P	19981223 (60)
	US 1999-129313P	19990414 (60)
	US 1999-164024P	19991104 (60)
	US 1999-169978P	19991210 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ADVANCED MEDICINE, INC., 901 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080

NUMBER OF CLAIMS: 71
EXEMPLARY CLAIM: 1
LINE COUNT: 4075
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are derivatives of glycopeptide compounds having at least one substituent of the formula:

--R.sup.a--Y--R.sup.b--(Z).sub.x

where R.sup.a, R.sup.b, Y, Z and x are as defined, and **pharmaceutical compositions** containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L65 ANSWER 5 OF 27 USPATFULL on STN
ACCESSION NUMBER: 2003:70918 USPATFULL
TITLE: Targeted nucleic acid constructs and uses related thereto
INVENTOR(S): Elmaleh, David R., Newton, MA, UNITED STATES
Fischman, Alan J., Boston, MA, UNITED STATES
Babich, John W., Scituate, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003049203	A1	20030313
APPLICATION INFO.:	US 2001-945166	A1	20010831 (9)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FOLEY HOAG, LLP, PATENT GROUP, WORLD TRADE CENTER WEST, 155 SEAPORT BLVD, BOSTON, MA, 02110
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Page(s)
LINE COUNT: 2270
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides targeted constructs comprising a targeting moiety, a nucleic acid, and a payload. The payload can be a detectable label or a therapeutic agent. The nucleic acid can be an antisense molecule that is complementary to RNA present in a target cell. The targeted constructs can be used to introduce the payload into a target cell in vivo or in vitro. Accordingly, the invention can be used for diagnostic purposes and for therapeutic purposes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L65 ANSWER 6 OF 27 USPATFULL on STN
ACCESSION NUMBER: 2003:183967 USPATFULL
TITLE: Photocleavable agents and conjugates for the detection and isolation of biomolecules
INVENTOR(S): Rothschild, Kenneth J., Newton, MA, United States
Sonar, Sanjay M., Boston, MA, United States
Olejnik, Jerzy, Allston, MA, United States
PATENT ASSIGNEE(S): The Trustees of Boston University, Boston, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6589736	B1	20030708
APPLICATION INFO.:	US 2000-504001		20000214 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-479389, filed on 7 Jun 1995, now patented, Pat. No. US 6057096 Continuation of Ser. No. US 1994-345807, filed on 22 Nov 1994, now patented, Pat. No. US 5986076
DOCUMENT TYPE: Utility

FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Riley, Jezia
LEGAL REPRESENTATIVE: Medlen & Carroll, LLP
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 26 Drawing Figure(s); 26 Drawing Page(s)
LINE COUNT: 3741
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to agents and conjugates that can be used to detect and isolate target components from complex mixtures such as nucleic acids from biological samples, cells from bodily fluids, and nascent proteins from translation reactions. Agents comprise a detectable moiety bound to a photoreactive moiety. Conjugates comprise agents coupled to substrates by covalent bounds which can be selectively cleaved with the administration of electromagnetic radiation. Targets substances labeled with detectable molecules can be easily identified and separated from a heterologous mixture of substances. Exposure of the conjugate to radiation releases the target in a functional form and completely unaltered. Using photocleavable molecular precursors as the conjugates, label can be incorporated into macromolecules, the nascent macromolecules isolated and the label completely removed. The invention also relates to targets isolated with these conjugates which may be useful as **pharmaceutical** agents or **compositions** that can be administered to humans and other mammals. Useful **compositions** include biological agents such as nucleic acids, proteins, lipids and cytokines. Conjugates can also be used to monitor the pathway and half-life of **pharmaceutical composition** in vivo and for diagnostic, therapeutic and prophylactic purposes. The invention also relates to kits comprised of agents and conjugates that can be used for the detection of diseases, disorders and nearly any individual substance in a complex background of substances.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L65 ANSWER 7 OF 27 USPATFULL on STN
ACCESSION NUMBER: 2003:40666 USPATFULL
TITLE: Desleucyl glycopeptide antibiotics and methods of making same
INVENTOR(S): Kahne, Daniel, Princeton, NJ, United States
Walker, Suzanne, Princeton, NJ, United States
PATENT ASSIGNEE(S): Trustees of Princeton University, Princeton, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6518243	B1	20030211
APPLICATION INFO.:	US 2000-540761		20000331 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-127516P	19990402 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Russel, Jeffrey E.
LEGAL REPRESENTATIVE: Kenyon & Kenyon
NUMBER OF CLAIMS: 40
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 2034
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds that are analogs of glycopeptide antibiotics are disclosed. The compounds have the formula A.sub.1-A.sub.2-A.sub.3-A.sub.4-A.sub.5-A.sub.6-A.sub.7 wherein each of the groups A.sub.2 to A.sub.7 is a modified or unmodified .alpha.-amino acid residue, A.sub.1 is optional and, when present, is an organic group other than N-substituted leucine,

and at least one of the groups A.sub.1 to A.sub.7 is linked via a glycosidic bond to one or more glycosidic groups each having one or more sugar residues, wherein at least one of said sugar residues is modified to bear at least one hydrophobic substituent. Methods of making these compounds, compositions including these compounds, and methods of using the compounds to treat infections in a host are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L65 ANSWER 8 OF 27 USPATFULL on STN

ACCESSION NUMBER:	2003:40665 USPATFULL
TITLE:	Derivatives of glycopeptide antibacterial agents
INVENTOR(S):	Chen, Qi-Qi, Irvine, CA, United States Griffin, John H., Atherton, CA, United States Jenkins, Thomas E., La Honda, CA, United States Judice, J. Kevin, Montara, CA, United States Linsell, Martin S., San Mateo, CA, United States Leadbetter, Michael R., San Leandro, CA, United States
PATENT ASSIGNEE(S):	Theravance, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6518242	B1	20030211	
APPLICATION INFO.:	US 1999-253670		19990219	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 1999-119162P	19990208	(60)
	US 1998-82209P	19980412	(60)
	US 1998-78903P	19980320	(60)
	US 1998-75514P	19980220	(60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Low, Christopher S. F.
ASSISTANT EXAMINER:	Gupta, Anish
LEGAL REPRESENTATIVE:	Boone, David E., Hagenah, Jeffrey A.
NUMBER OF CLAIMS:	18
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT:	4500

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel antibacterial agents that act as multibinding agents are disclosed. The compounds of the invention comprise from 2-10 ligands covalently connected, each of said ligands being capable of binding to a transglycosylase enzyme substrate thereby modulating the biological processes/functions thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L65 ANSWER 9 OF 27 IFIPAT COPYRIGHT 2003 IFI on STN DUPLICATE 1

AN	10133658 IFIPAT;IFIUDB;IFICDB
TITLE:	**PHARMACEUTICAL COMPOSITIONS** CONTAINING A GLYCOPEPTIDE ANTIBIOTIC AND A CYCLODEXTRIN; FOR THERAPY OF BACTERIAL DISEASE IN A MAMMAL; SIDE EFFECT REDUCTION
INVENTOR(S):	Conner; Michael W., Half Moon Bay, CA, US Judice; J. Kevin, El Granada, CA, US Mu; YongQi, Los Altos, CA, US Shaw; Jeng-Pyng, Saratoga, CA, US
PATENT ASSIGNEE(S):	Unassigned
AGENT:	SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A., P.O. BOX 2938, MINNEAPOLIS, MN, 55402, US

	NUMBER	PK	DATE

PATENT INFORMATION: US 2002077280 A1 20020620
APPLICATION INFORMATION: US 2001-846893 20010501

	NUMBER	DATE
PRIORITY APPLN. INFO.:	US 2000-201178P	20000502 (Provisional)
	US 2000-213146P	20000622 (Provisional)
	US 2000-213410P	20000622 (Provisional)
	US 2000-213415P	20000622 (Provisional)
	US 2000-213417P	20000622 (Provisional)
	US 2000-213428P	20000622 (Provisional)
	US 2000-226727P	20000818 (Provisional)

FAMILY INFORMATION: US 2002077280 20020620
DOCUMENT TYPE: Utility
Patent Application - First Publication
FILE SEGMENT: CHEMICAL
APPLICATION
NUMBER OF CLAIMS: 19
AB Disclosed are **pharmaceutical compositions** containing a cyclodextrin and a therapeutically effective amount of a glycopeptide antibiotic or a salt thereof. Also disclosed are methods of treating a bacterial disease in a mammal by administering such **pharmaceutical compositions**.
CLMN 19

L65 ANSWER 10 OF 27 USPATFULL on STN
ACCESSION NUMBER: 2002:119586 USPATFULL
TITLE: Identification of essential genes in prokaryotes
INVENTOR(S): Haselbeck, Robert, San Diego, CA, UNITED STATES
Ohlsen, Kari L., San Diego, CA, UNITED STATES
Zyskind, Judith W., La Jolla, CA, UNITED STATES
Wall, Daniel, San Diego, CA, UNITED STATES
Trawick, John D., La Mesa, CA, UNITED STATES
Carr, Grant J., Escondido, CA, UNITED STATES
Yamamoto, Robert T., San Diego, CA, UNITED STATES
Xu, H. Howard, San Diego, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002061569	A1	20020523	
APPLICATION INFO.:	US 2001-815242	A1	20010321	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-191078P	20000321 (60)
	US 2000-206848P	20000523 (60)
	US 2000-207727P	20000526 (60)
	US 2000-242578P	20001023 (60)
	US 2000-253625P	20001127 (60)
	US 2000-257931P	20001222 (60)
	US 2001-269308P	20010216 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: KNOBBE MARTENS OLSON & BEAR LLP, 620 NEWPORT CENTER DRIVE, SIXTEENTH FLOOR, NEWPORT BEACH, CA, 92660
NUMBER OF CLAIMS: 44
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 30870
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The sequences of antisense nucleic acids which inhibit the proliferation of prokaryotes are disclosed. Cell-based assays which employ the antisense nucleic acids to identify and develop antibiotics are also disclosed. The antisense nucleic acids can also be used to identify proteins required for proliferation, express these proteins or portions thereof, obtain antibodies capable of specifically binding to the

expressed proteins, and to use those expressed proteins as a screen to isolate candidate molecules for rational drug discovery programs. The nucleic acids can also be used to screen for homologous nucleic acids that are required for proliferation in cells other than Staphylococcus aureus, Salmonella typhimurium, Klebsiella pneumoniae, and Pseudomonas aeruginosa. The nucleic acids of the present invention can also be used in various assay systems to screen for proliferation required genes in other organisms.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L65 ANSWER 11 OF 27 USPATFULL on STN
ACCESSION NUMBER: 2002:304059 USPATFULL
TITLE: Uridyl peptide antibiotic (UPA) derivatives, their synthesis and use
INVENTOR(S): Boojamra, Constantine G., San Francisco, CA, United States
Lemoine, Remy C., San Francisco, CA, United States
Hecker, Scott, Los Gatos, CA, United States
Lee, Ving J., Los Altos, CA, United States
Leger, Roger, San Francisco, CA, United States
PATENT ASSIGNEE(S): Essential Therapeutics, Inc., Mountain View, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6482921	B1	20021119
APPLICATION INFO.:	US 1999-330503		19990611 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-117911P	19990128 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Low, Christopher S. F.
ASSISTANT EXAMINER: Lukton, David
LEGAL REPRESENTATIVE: Bingham McCutchen LLP, Rose, Bernard F.
NUMBER OF CLAIMS: 31
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 3597
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to dihydro derivatives of the uridyl peptide antibiotics mureidomycin, pacidimycin and napsamycin which have antibiotic activity against a number of bacterial strains including strains resistant to current therapeutic antibiotics.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L65 ANSWER 12 OF 27 USPATFULL on STN
ACCESSION NUMBER: 2002:246836 USPATFULL
TITLE: Glycopeptide derivatives and **pharmaceutical compositions** containing the same
INVENTOR(S): Judice, J. Kevin, El Granada, CA, United States
Fatheree, Paul Ross, San Francisco, CA, United States
Lam, Bernice M. T., San Francisco, CA, United States
Leadbetter, Michael, San Leandro, CA, United States
linsell, Martin Sheringham, San Mateo, CA, United States
Mu, YongQi, Los Altos, CA, United States
Trapp, Sean Gary, San Francisco, CA, United States
Yang, Guang, Foster City, CA, United States
Zhu, Yan, Foster City, CA, United States
PATENT ASSIGNEE(S): Theravance, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6455669	B1	20020924
APPLICATION INFO.:	US 2000-674456		20001101 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-113728P	19981223 (60)
	US 1999-129313P	19990414 (60)
	US 1999-164024P	19991104 (60)
	US 1999-169978P	19991210 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Low, Christopher S. F.
ASSISTANT EXAMINER: Lukton, David
LEGAL REPRESENTATIVE: Boone, David E., Hagenah, Jeffrey A.
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 3281
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are derivatives of glycopeptide compounds having at least one substituent of the formula:

--R.sup.a--Y--R.sup.b--(Z).sub.x

where R.sup.a, R.sup.b, Y, Z and x are as defined, and **pharmaceutical compositions** containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L65 ANSWER 13 OF 27 USPATFULL on STN
ACCESSION NUMBER: 2002:224698 USPATFULL
TITLE: Glycopeptide derivatives and **pharmaceutical compositions** containing the same
INVENTOR(S): Judice, J. Kevin, El Granada, CA, United States
Fatheree, Paul Ross, San Francisco, CA, United States
Lam, Bernice M. T., San Francisco, CA, United States
Leadbetter, Michael R., San Leandro, CA, United States
Linsell, Martin S., San Mateo, CA, United States
Mu, YongQi, Los Altos, CA, United States
Trapp, Sean Gary, San Francisco, CA, United States
Yang, Guang, San Mateo, CA, United States
Zhu, Yan, Foster City, CA, United States
PATENT ASSIGNEE(S): Advanced Medicine, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6444786	B1	20020903
APPLICATION INFO.:	US 2000-656473		20000906 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1999-470209, filed on 22 Dec 1999, now patented, Pat. No. US 6392012		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-113728P	19981223 (60)
	US 1999-129313P	19990414 (60)
	US 1999-164024P	19991104 (60)
	US 1999-169978P	19991210 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Low, Christopher S. F.
ASSISTANT EXAMINER: Lukton, David

LEGAL REPRESENTATIVE: Boone, David E., Hagenah, Jeffrey A.
NUMBER OF CLAIMS: 32
EXEMPLARY CLAIM: 1,2,31,32
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 3267
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are derivatives of glycopeptide compounds having at least one substituent of the formula:

--R.sup.a--Y--R.sup.b--(Z).sub.x

where R.sup.a, R.sup.b, Y, Z and x are as defined, and **pharmaceutical compositions** containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L65 ANSWER 14 OF 27 USPATFULL on STN
ACCESSION NUMBER: 2002:144095 USPATFULL
TITLE: Betaines as adjuvants to susceptibility testing and antimicrobial therapy
INVENTOR(S): Thornton, Charles G., Gaithersburg, MD, United States
PATENT ASSIGNEE(S): Integrated Research Technology, LLC, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6406880	B1	20020618
APPLICATION INFO.:	US 1999-429614		19991029 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 1998-US8760, filed on 1 May 1998

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-45512P	19970502 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Woodward, Michael P.
ASSISTANT EXAMINER: Moran, Marjorie A.
LEGAL REPRESENTATIVE: Sterne, Kessler, Goldstein & Fox P.L.L.C.
NUMBER OF CLAIMS: 64
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 94 Drawing Figure(s); 55 Drawing Page(s)
LINE COUNT: 4477
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is related to methods and compositions for susceptibility testing of bacteria containing mycolic acid structures using betaine-like detergents, and inducing the susceptibility of such bacteria using the same.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L65 ANSWER 15 OF 27 USPATFULL on STN
ACCESSION NUMBER: 2002:116382 USPATFULL
TITLE: Glycopeptide derivatives and **pharmaceutical compositions** containing the same
INVENTOR(S): Judice, J. Kevin, El Granada, CA, United States
Fatheree, Paul Ross, San Francisco, CA, United States
Lam, Bernice M. T., San Francisco, CA, United States
Leadbetter, Michael R., San Leandro, CA, United States
Linsell, Martin S., San Mateo, CA, United States
Mu, YongQi, Los Altos, CA, United States
Trapp, Sean Gary, San Francisco, CA, United States
Yang, Guang, San Mateo, CA, United States
Zhu, Yan, Foster City, CA, United States

PATENT ASSIGNEE(S): Advanced Medicine, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6392012	B1	20020521
APPLICATION INFO.:	US 1999-470209		19991222 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-113728P	19981223 (60)
	US 1999-129313P	19990414 (60)
	US 1999-164024P	19991104 (60)
	US 1999-169978P	19991210 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Low, Christopher S. F.
ASSISTANT EXAMINER: Lukton, David
LEGAL REPRESENTATIVE: Boone, David E., Hagenah, Jeffrey A.
NUMBER OF CLAIMS: 36
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 3301
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are derivatives of glycopeptide compounds having at least one substituent of the formula:

--R.sup.a--Y--R.sup.b--(Z).sub.x

where R.sup.a, R.sup.b, Y, Z and x are as defined, and **pharmaceutical compositions** containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L65 ANSWER 16 OF 27 USPATFULL on STN
ACCESSION NUMBER: 2001:190752 USPATFULL
TITLE: Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
INVENTOR(S): Setterstrom, Jean A., Alpharetta, GA, United States
Van Hamont, John E., Fort Meade, MD, United States
Reid, Robert H., McComas, CT, United States
Jacob, Elliot, Silver Spring, MD, United States
Jeyanthi, Ramasubbu, Columbia, MD, United States
Boedeker, Edgar C., Chevy Chase, MD, United States
McQueen, Charles E., Olney, MD, United States
Jarboe, Daniel L., Silver Spring, MD, United States
Cassels, Frederick, Ellicott City, MD, United States
Brown, William, Denver, CO, United States
Thies, Curt, Ballwin, MO, United States
Tice, Thomas R., Birmington, AL, United States
Roberts, F. Donald, Dover, MA, United States
Friden, Phil, Beford, MA, United States(4)
PATENT ASSIGNEE(S): The United States of America as represented by the Secretary of the Army, Washington, DC, United States (U.S. government)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6309669	B1	20011030
APPLICATION INFO.:	US 1997-789734		19970127 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1996-590973, filed on 24 Jan 1996, now abandoned Continuation-in-part of Ser. No. US 1995-446149, filed on 22 May 1995, now		

abandoned Continuation of Ser. No. US 1984-590308, filed on 6 Mar 1984, now abandoned And Ser. No. US 789734 Continuation-in-part of Ser. No. US 1995-446148, filed on 22 May 1995 Continuation-in-part of Ser. No. US 1992-867301, filed on 10 Apr 1992, now patented, Pat. No. US 5417986, issued on 23 May 1995 Continuation-in-part of Ser. No. US 1984-590308, filed on 16 Mar 1984, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Harrison, Robert H.
LEGAL REPRESENTATIVE: Nash, Caroline, Arwine, Elizabeth
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 87 Drawing Figure(s); 85 Drawing Page(s)
LINE COUNT: 6182
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel burst-free, sustained release biocompatible and biodegrable microcapsules which can be programmed to release their active core for variable durations ranging from 1-100 days in an aqueous physiological environment. The microcapsules are comprised of a core of polypeptide or other biologically active agent encapsulated in a matrix of poly(lactide/glycolide) copolymer, which may contain a pharmaceutically-acceptable adjuvant, as a blend of upcapped free carboxyl end group and end-capped forms ranging in ratios from 100/0 to 1/99.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L65 ANSWER 17 OF 27 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN
ACCESSION NUMBER: 2002-049313 [06] WPIDS
CROSS REFERENCE: 2002-066518 [09]; 2002-121888 [16]; 2002-147791 [19]; 2002-195669 [25]; 2002-205901 [26]; 2002-205902 [26]
DOC. NO. CPI: C2002-013861
TITLE: Use of cyclodextrin in conjunction with glycopeptide antibiotics reduces their tissue accumulation, nephrotoxicity, histamine release and vascular irritation, useful for treating bacterial diseases.
DERWENT CLASS: B02 B04
INVENTOR(S): CONNER, M W; JUDICE, K; MU, Y; PACE, J; SHAW, J; JUDICE, J K; PACE, J L; LEADBETTER, M R; LINSELL, M S; SCHMIDT, D E; YANG, G
PATENT ASSIGNEE(S): (ADME-N) ADVANCED MEDICINE INC; (CONN-I) CONNER M W; (JUDI-I) JUDICE J K; (MUYY-I) MU Y; (SHAW-I) SHAW J; (THER-N) THERAVANCE INC; (SCHM-I) SCHMIDT D E; (YANG-I) YANG G
COUNTRY COUNT: 96
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2001082971	A2	20011108	(200206)*	EN	61
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW					
AU 2001059306	A	20011112	(200222)		
US 2002049156	A1	20020425	(200233)		
US 2002077280	A1	20020620	(200244)		
EP 1278549	A2	20030129	(200310)	EN	
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI TR					
NO 2002005954	A	20021211	(200317)		
KR 2002093110	A	20021212	(200328)		

BR 2001010530 A 20030408 (200329)
KR 2003032970 A 20030426 (200354)

APPLICATION DETAILS:

PATENT NO	KIND		APPLICATION	DATE
WO 2001082971	A2		WO 2001-US14000	20010501
AU 2001059306	A		AU 2001-59306	20010501
US 2002049156	A1	Provisional	US 2000-213428P	20000622
			US 2001-847061	20010501
US 2002077280	A1	Provisional	US 2000-201178P	20000502
		Provisional	US 2000-213146P	20000622
		Provisional	US 2000-213410P	20000622
		Provisional	US 2000-213415P	20000622
		Provisional	US 2000-213417P	20000622
		Provisional	US 2000-213428P	20000622
		Provisional	US 2000-226727P	20000818
			US 2001-846893	20010501
EP 1278549	A2		EP 2001-932810	20010501
			WO 2001-US14000	20010501
NO 2002005954	A		WO 2001-US13998	20010501
			NO 2002-5954	20021211
KR 2002093110	A		KR 2002-714644	20021101
BR 2001010530	A		BR 2001-10530	20010501
			WO 2001-US14000	20010501
KR 2003032970	A		KR 2002-717472	20021221

FILING DETAILS:

PATENT NO	KIND		PATENT NO
AU 2001059306	A	Based on	WO 2001082971
EP 1278549	A2	Based on	WO 2001082971
BR 2001010530	A	Based on	WO 2001082971

PRIORITY APPLN. INFO: US 2000-226727P 20000818; US 2000-201178P 20000502; US 2000-213146P 20000622; US 2000-213410P 20000622; US 2000-213415P 20000622; US 2000-213417P 20000622; US 2000-213428P 20000622; US 2001-847061 20010501; US 2001-846893 20010501; US 2000-213148P 20000622

AN 2002-049313 [06] WPIDS

CR 2002-066518 [09]; 2002-121888 [16]; 2002-147791 [19]; 2002-195669 [25]; 2002-205901 [26]; 2002-205902 [26]

AB WO 200182971 A UPAB: 20030821

NOVELTY - Composition comprising a cyclodextrin and a glycopeptide antibiotic or one of its salts, is new.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a **pharmaceutical composition** comprising an aqueous cyclodextrin carrier and a glycopeptide antibiotic or one of its salts.

ACTIVITY - Antibacterial.

MECHANISM OF ACTION - None given.

USE - The compositions are for treating bacterial diseases, as well as for reducing tissue accumulation of glycopeptide antibiotics, and nephrotoxicity, histamine release and vascular irritation produced by glycopeptide antibiotics (claimed). The compositions are particularly useful for treating Gram-positive microorganisms, in particular methicillin-resistant staphylococci.

ADVANTAGE - By reducing the undesirable effects of glycopeptides, administration of the glycopeptide with a cyclodextrin increases the therapeutic window for glycopeptides, and allows a greater amount to be administered. Compared to cyclodextrin-free compositions, the compositions of the invention exhibit one or more of the following: reduced tissue accumulation of glycopeptide antibiotics, reduced nephrotoxicity, reduced

histamine release and reduced vascular irritation. The compositions are highly effective at treating bacterial diseases.
Dwg.0/0

L65 ANSWER 18 OF 27 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN
ACCESSION NUMBER: 2001-191490 [19] WPIDS
CROSS REFERENCE: 2001-183037 [18]
DOC. NO. CPI: C2001-057379
TITLE: Oral drug delivery composition comprises a drug substance, sugar, and a gas generating component and provides prolonged gastric retention.
DERWENT CLASS: A96 B05
INVENTOR(S): STANIFORTH, J N; TALWAR, N; TOBYN, M J
PATENT ASSIGNEE(S): (RANB-N) RANBAXY LAB LTD
COUNTRY COUNT: 95
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2001010419	A1	20010215	(200119)*	EN	46
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TZ UG ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW					
AU 2000063099	A	20010305	(200130)		
EP 1206249	A1	20020522	(200241)	EN	
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI					
BR 2000012981	A	20020618	(200249)		
SK 2002000183	A3	20020806	(200261)		
CZ 2002000415	A3	20020814	(200263)		
ZA 2002000926	A	20021127	(200305)		51
HU 2002002497	A2	20021128	(200309)		
CN 1376059	A	20021023	(200313)		
JP 2003506400	W	20030218	(200315)		32

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2001010419	A1	WO 2000-IB1083	20000801
AU 2000063099	A	AU 2000-63099	20000801
EP 1206249	A1	EP 2000-949840	20000801
		WO 2000-IB1083	20000801
BR 2000012981	A	BR 2000-12981	20000801
		WO 2000-IB1083	20000801
SK 2002000183	A3	WO 2000-IB1083	20000801
		SK 2002-183	20000801
CZ 2002000415	A3	WO 2000-IB1083	20000801
		CZ 2002-415	20000801
ZA 2002000926	A	ZA 2002-926	20020201
HU 2002002497	A2	WO 2000-IB1083	20000801
		HU 2002-2497	20000801
CN 1376059	A	CN 2000-813344	20000801
JP 2003506400	W	WO 2000-IB1083	20000801
		JP 2001-514939	20000801

FILING DETAILS:

PATENT NO	KIND		PATENT NO
AU 2000063099	A	Based on	WO 2001010419
EP 1206249	A1	Based on	WO 2001010419
BR 2000012981	A	Based on	WO 2001010419

SK 2002000183 A3 Based on WO 2001010419
CZ 2002000415 A3 Based on WO 2001010419
HU 2002002497 A2 Based on WO 2001010419
JP 2003506400 W Based on WO 2001010419

PRIORITY APPLN. INFO: WO 1999-IB1386 19990804
AN 2001-191490 [19] WPIDS
CR 2001-183037 [18]
AB WO 200110419 A UPAB: 20030303
NOVELTY - Oral drug delivery composition for prolonged gastric retention has a highly porous matrix, and comprises: at least one drug substance; sugar; and a gas generating component which is a combination of at least one thermostable and at least one thermolabile component.

DETAILED DESCRIPTION - Oral drug delivery composition for prolonged gastric retention has a highly porous matrix, and comprises: at least one drug substance; sugar; a gas generating component which is a combination of at least one thermostable and at least one thermolabile component; and optionally auxiliary components. The composition maintains its hydrodynamic balance and physical integrity while the drug is released in the stomach.

USE - The composition is used for the oral delivery of drugs, preferably selected from an antiulcer, analgesic, antihypertensive, antibiotic, antipsychotic, anticancer, antimuscarinic, diuretic, antimigraine, antiviral, anti-inflammatory, sedative, antidiabetic, antidepressant, antihistamine, antiparasitic, antiepileptic, and/or lipid lowering drug (claimed).

ADVANTAGE - The composition selectively delivers drugs at gastric levels and in upper parts of the small intestine over an extended period of time. The composition contains a gas generating agent which generates a gas to form a highly porous matrix with good floating characteristics, and also generates a gas on contact with gastric fluid which helps retain the buoyancy of the dosage form in the stomach.
Dwg.0/0

L65 ANSWER 19 OF 27 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN
ACCESSION NUMBER: 2001-182775 [18] WPIDS
DOC. NO. CPI: C2001-054501
TITLE: New polypeptide dendrimers useful as carriers for delivery of bioactive substances e.g. drugs, antigens and diagnostic imaging contrast agents, has multifunctional core with branched polypeptide chains.
DERWENT CLASS: B04 D16
INVENTOR(S): VERDINI, A
PATENT ASSIGNEE(S): (VERD-I) VERDINI A; (SERV-N) LES LAB SERVIER
COUNTRY COUNT: 95
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2001007469	A2	20010201	(200118)*	EN	33
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TZ UG ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW					
AU 2000062766	A	20010213	(200128)		
NO 2002000333	A	20020122	(200231)		
EP 1200461	A2	20020502	(200236)	EN	
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI					
HU 2002001975	A2	20021028	(200277)		
CN 1364171	A	20020814	(200280)		
IT 1313089	B	20020530	(200282)		
JP 2003506326	W	20030218	(200315)		42
NZ 517231	A	20030530	(200341)		

ZA 2002001089 A 20030730 (200355) 33

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2001007469	A2	WO 2000-EP7022	20000721
AU 2000062766	A	AU 2000-62766	20000621
NO 2002000333	A	WO 2000-EP7022	20000721
		NO 2002-333	20020122
EP 1200461	A2	EP 2000-949393	20000721
		WO 2000-EP7022	20000721
HU 2002001975	A2	WO 2000-EP7022	20000721
		HU 2002-1975	20000721
CN 1364171	A	CN 2000-810769	20000721
IT 1313089	B	IT 1999-FO15	19990723
JP 2003506326	W	WO 2000-EP7022	20000721
		JP 2001-512552	20000721
NZ 517231	A	NZ 2000-517231	20000721
		WO 2000-EP7022	20000721
ZA 2002001089	A	ZA 2002-1089	20020207

FILING DETAILS:

PATENT NO	KIND		PATENT NO
AU 2000062766	A	Based on	WO 2001007469
EP 1200461	A2	Based on	WO 2001007469
HU 2002001975	A2	Based on	WO 2001007469
JP 2003506326	W	Based on	WO 2001007469
NZ 517231	A	Based on	WO 2001007469

PRIORITY APPLN. INFO: IT 1999-FO15 19990723
AN 2001-182775 [18] WPIDS
AB WO 200107469 A UPAB: 20010402

NOVELTY - Polypeptide dendrimer (I) having a multifunctional core and an exterior of closely spaced groups constituting the terminals of branched polypeptide chains (monodendrons) radially attached to the core that, in turn form an interior layers (generations) of short peptide branching units (propagators) with characteristic hollows and channels, is new.

DETAILED DESCRIPTION - New polypeptide dendrimer (I) has a multifunctional core and an exterior of closely spaced groups constituting the terminals of branched polypeptide chains (monodendrons) radially attached to the core that, in turn form interior layers (generations) of short peptide branching units (propagators) with characteristic hollows and channels.

Each propagator contains a trifunctional amino acid whose asymmetric carbon (the propagator branching point) is connected to two equal-length arms bearing identical terminal reactive groups and to a third arm (the propagator stem) bearing an activatable functional group of formula K-(L)p-M (I).

K = multifunctional core group;

L = polypeptide monodendron;

p = number of polypeptide monodendrons irradiating from the core group and

M = outermost ramifications of the dendrimer.

INDEPENDENT CLAIMS are also included for the following:

(1) production of (I);

(2) entrapping into (I) bioactive substances and drugs with molecular weights less than 1000 Da, by adding (I) to a concentrated or saturated solution of the molecules and precipitating the loaded (I) after 24 hours incubation at room temperature in a large volume of a precipitant;

(3) entrapping into (I) bioactive substances and drugs with molecular weight higher than 1000 Da, by the selective chemical ligation of polypeptide monodendrons in aqueous buffers, to the core groups in the presence of the molecules;

(4) selective chemical ligation of bioactive substances and drugs to the internal functional groups of (I) in aqueous buffer, after loading the dendrimer carrier by diffusion, and

(5) **compositions** with **pharmaceutically** acceptable excipients, where (I) is the unimolecular carrier or bioactive molecule covalently linked or entrapped into (I).

ACTIVITY - Cytostatic; virucide; gene therapy; vaccine.

N(CH2-CH2-NH-CO-CH(CH2-phenyl)-NH-Gly-Gly-Orn-Gly (Gly-Gly-Orn-Gly(Gly-Gly-Orn-Gly(Gly-Gly-Orn-Gly-H)2)2)2)3 was conjugated with NANPNANP and the adjuvant property of the antigen-dendrimer conjugate was assessed. Groups of BALB/c female mice were injected with 500 mu g of antigen-dendrimer conjugate dissolved in 50 ml of water. C57/8L/6 mice were injected with 50 mu g of NANPNANP dissolved in 50 mu l of water. After three weeks, 25 and 250 mu g of the same products were injected again to the two groups of mice. 10 days after, a sample of blood was taken from each mice. The sera were tested by an ELISA test employing (NANP)40 as the antigen. The antigen-dendrimer conjugate showed higher anti-NANP antibody titers at week 45 (4.10 plus or minus 0.01) as compared to NANPNANP antigen (2.81 plus or minus 08).

MECHANISM OF ACTION - None given.

USE - Useful as unimolecular carriers of bioactive molecules, such as amino acid, peptide, protein, nucleotide, oligonucleotide, **lipid**. , **saccharide**, oligosaccharide, small organic molecule or their synthetic analogs, derivatives or drugs, cellular receptor ligands, bacterial, viral and parasite antigens, gene-therapy compounds, anticancer drugs, **antibiotics** and antiviral substances and as diagnostic imaging contrast agents (claimed). Unimolecular carrier polypeptide dendrimers/guest molecules system are used in chemotherapy of cancer, anticoagulant and clot-dissolving drug therapy, antiviral therapy, vaccines, controlled release of hormones and related bioactive substances.

ADVANTAGE - The polypeptide dendrimers have enhanced stability to plasma and cellular enzymes and the dimension of the dendrimer can be regulated easily which facilitates to balance the retention and excretion of the dendrimer carriers in the body.

Dwg.0/0

L65 ANSWER 20 OF 27 USPATFULL on STN

ACCESSION NUMBER:	2000:53880 USPATFULL
TITLE:	Photocleavable agents and conjugates for the detection and isolation of biomolecules
INVENTOR(S):	Rothschild, Kenneth J., Newton, MA, United States Sonar, Sanjay M., Boston, MA, United States Olejnik, Jerzy, Allston, MA, United States
PATENT ASSIGNEE(S):	The Trustees of Boston University, Boston, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6057096		20000502
APPLICATION INFO.:	US 1995-479389		19950607 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-479389, filed on 7 Jun 1995 which is a continuation of Ser. No. US 1994-345807, filed on 22 Nov 1994 which is a continuation-in-part of Ser. No. US 1994-240511, filed on 11 May 1994, now patented, Pat. No. US 5643722		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Marschel, Ardin H.		
ASSISTANT EXAMINER:	Riley, Jezia		
LEGAL REPRESENTATIVE:	Medlen & Carroll, LLP		
NUMBER OF CLAIMS:	64		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	26 Drawing Figure(s); 26 Drawing Page(s)		
LINE COUNT:	4007		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to agents and conjugates that can be used to

detect and isolate target components from complex mixtures such as nucleic acids from biological samples, cells from bodily fluids, and nascent proteins from translation reactions. Agents comprise a detectable moiety bound to a photoreactive moiety. Conjugates comprise agents coupled to substrates by covalent bounds which can be selectively cleaved with the administration of electromagnetic radiation. Targets substances labeled with detectable molecules can be easily identified and separated from a heterologous mixture of substances. Exposure of the conjugate to radiation releases the target in a functional form and completely unaltered. Using photocleavable molecular precursors as the conjugates, label can be incorporated into macromolecules, the nascent macromolecules isolated and the label completely removed. The invention also relates to targets isolated with these conjugates which may be useful as **pharmaceutical** agents or **compositions** that can be administered to humans and other mammals. Useful **compositions** include biological agents such as nucleic acids, proteins, lipids and cytokines. Conjugates can also be used to monitor the pathway and half-life of **pharmaceutical composition** in vivo and for diagnostic, therapeutic and prophylactic purposes. The invention also relates to kits comprised of agents and conjugates that can be used for the detection of diseases, disorders and nearly any individual substance in a complex background of substances.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L65 ANSWER 21 OF 27 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN
ACCESSION NUMBER: 2001-015689 [02] WPIDS
DOC. NO. CPI: C2001-004136
TITLE: Compositions comprising monoacyl membrane lipids, a lipophilic and a hydrophilic component are useful for delivering hydro- and lipophilic compounds with improved bioavailability and low toxicity .
DERWENT CLASS: A96 B07
INVENTOR(S): LEIGH, M L S; LEIGH, S
PATENT ASSIGNEE(S): (PHAR-N) PHARES PHARM RES NV
COUNTRY COUNT: 93
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2000061113	A1	20001019	(200102)*	EN	40

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SL SZ TZ UG ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AU 2000039804 A 20001114 (200108)
EP 1169020 A1 20020109 (200205) EN
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2000061113	A1	WO 2000-GB1361	20000411
AU 2000039804	A	AU 2000-39804	20000411
EP 1169020	A1	EP 2000-919049	20000411
		WO 2000-GB1361	20000411

FILING DETAILS:

PATENT NO	KIND	PATENT NO

AU 2000039804 A Based on WO 2000061113
EP 1169020 A1 Based on WO 2000061113

PRIORITY APPLN. INFO: GB 1999-8309 19990412
AN 2001-015689 [02] WPIDS
AB WO 200061113 A UPAB: 20010110
NOVELTY - Compositions for delivery of lipophilic and hydrophilic compounds comprise monoacyl and preferably also diacyl membrane lipids with a lipophilic and a hydrophilic component.

DETAILED DESCRIPTION - A composition for delivery of an active compound comprises micelle-forming membrane lipids and contains at least one lipophilic and one hydrophilic component which render the composition into a homogenous liquid, gel or semi-solid which yields dispersed lipid aggregates below 1000 nm when diluted in an aqueous medium.

INDEPENDENT CLAIMS are included for:

(1) a liquid composition comprising (a) a mixture of membrane lipids comprising a micelle-forming lipid and a bilayer-forming lipid, (b) a lipophilic component, (c) sufficient ethanol to mobilize the lipids and (d) sufficient polyol to maintain the lipids in solution at room temperature;

(2) a liquid composition comprising (a) a mixture of membrane lipids comprising a micelle-forming lipid and a bilayer-forming lipid, (b) a lipophilic component, (c) sufficient water to hydrate the lipid mixture and (d) an active compound;

(3) a method of forming lipid aggregates below 1000 nm comprising adding water in situ and/or in vivo to the composition;

(4) use of the composition for oral, pulmonary, topical, mucosal or tissue irrigation to enhance penetration of the active compound compared to the drug alone; and

(5) a process for dispersing a biologically active compound comprising dispersing a micelle-forming membrane lipid and an active compound to form a clear liquid, gel or semi-solid and mixing this with an aqueous medium for form dispersed lipid aggregates below 1000 nm with the active compound in solution or stable dispersion.

USE - The composition is useful for delivering lipophilic and hydrophilic compounds with improved bioavailability, less variability, low toxicity and ease of use in enhancing penetration.

Dwg.0/1

L65 ANSWER 22 OF 27 USPATFULL on STN

ACCESSION NUMBER:	1999:146775 USPATFULL
TITLE:	Photocleavable agents and conjugates for the detection and isolation of biomolecules
INVENTOR(S):	Rothschild, Kenneth J., Newton, MA, United States Sonar, Sanjay M., Boston, MA, United States Olejnik, Jerzy, Allston, MA, United States
PATENT ASSIGNEE(S):	Trustees of Boston University, Boston, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5986076		19991116
APPLICATION INFO.:	US 1994-345807		19941122 (8)

RELATED APPLN. INFO.:	Continuation of Ser. No. US 1994-345807, filed on 22 Nov 1994 which is a continuation-in-part of Ser. No. US 1994-240511, filed on 11 May 1994
DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Marschel, Ardin H.
ASSISTANT EXAMINER:	Riley, Jezia
LEGAL REPRESENTATIVE:	Medlen & Carroll, LLP
NUMBER OF CLAIMS:	50
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	25 Drawing Figure(s); 26 Drawing Page(s)
LINE COUNT:	3996

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to agents and conjugates that can be used to detect and isolate target components from complex mixtures such as nucleic acids from biological samples, cells from bodily fluids, and nascent proteins from translation reactions. Agents comprise a detectable moiety bound to a photoreactive moiety. Conjugates comprise agents coupled to substrates by covalent bounds which can be selectively cleaved with the administration of electromagnetic radiation. Targets substances labeled with detectable molecules can be easily identified and separated from a heterologous mixture of substances. Exposure of the conjugate to radiation releases the target in a functional form and completely unaltered. Using photocleavable molecular precursors as the conjugates, label can be incorporated into macromolecules, the nascent macromolecules isolated and the label completely removed. The invention also relates to targets isolated with these conjugates which may be useful as **pharmaceutical** agents or **compositions** that can be administered to humans and other mammals. Useful **compositions** include biological agents such as nucleic acids, proteins, lipids and cytokines. Conjugates can also be used to monitor the pathway and half-life of **pharmaceutical composition** in vivo and for diagnostic, therapeutic and prophylactic purposes. The invention also relates to kits comprised of agents and conjugates that can be used for the detection of diseases, disorders and nearly any individual substance in a complex background of substances.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L65 ANSWER 23 OF 27 USPATFULL on STN

ACCESSION NUMBER:	1999:106302 USPATFULL
TITLE:	Methods for the detection and isolation of biomolecules
INVENTOR(S):	Rothschild, Kenneth J., 97 Dorcar Rd., Newton, MA, United States 02159 Sonar, Sanjay M., 1575 Tremont St., Apt. 306, Boston, MA, United States 02120 Olejnik, Jerzy, 1307 Commonwealth Ave., Allston, MA, United States 02134

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5948624		19990907
APPLICATION INFO.:	US 1997-978897		19971126 (8)

RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-487909, filed on 7 Jun 1995, now abandoned which is a continuation of Ser. No. US 1994-345807, filed on 22 Nov 1994 which is a continuation-in-part of Ser. No. US 1994-240511, filed on 11 May 1994, now patented, Pat. No. US 5643722
DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Marschel, Ardin H.
ASSISTANT EXAMINER:	Riley, Jezia
NUMBER OF CLAIMS:	39
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	25 Drawing Figure(s); 26 Drawing Page(s)
LINE COUNT:	3916

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to agents and conjugates that can be used to detect and isolate target components from complex mixtures such as nucleic acids from biological samples, cells from bodily fluids, and nascent proteins from translation reactions. Agents comprise a detectable moiety bound to a photoreactive moiety. Conjugates comprise agents coupled to substrates by covalent bounds which can be selectively cleaved with the administration of electromagnetic radiation. Targets substances labeled with detectable molecules can be easily identified and separated from a heterologous mixture of substances. Exposure of the conjugate to radiation releases the target in a functional form and completely unaltered. Using photocleavable molecular precursors as the

conjugates, label can be incorporated into macromolecules, the nascent macromolecules isolated and the label completely removed. The invention also relates to targets isolated with these conjugates which may be useful as **pharmaceutical** agents or **compositions** that can be administered to humans and other mammals. Useful **compositions** include biological agents such as nucleic acids, proteins, lipids and cytokines. Conjugates can also be used to monitor the pathway and half-life of **pharmaceutical composition** in vivo and for diagnostic, therapeutic and prophylactic purposes. The invention also relates to kits comprised of agents and conjugates that can be used for the detection of diseases, disorders and nearly any individual substance in a complex background of substances.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L65 ANSWER 24 OF 27 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN
ACCESSION NUMBER: 1999-540749 [45] WPIDS
DOC. NO. CPI: C1999-157979
TITLE: Composition for delivering biologically active compound to living organism.
DERWENT CLASS: A18 A25 A96 B07
INVENTOR(S): LEIGH, M L S; LEIGH, S
PATENT ASSIGNEE(S): (PHAR-N) PHARES PHARM RES NV
COUNTRY COUNT: 85
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9944642	A1	19990910	(199945)*	EN	48
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SL SZ UG ZW					
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW					
AU 9928455	A	19990920	(200007)		
EP 1059941	A1	20001220	(200105)	EN	
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE					
JP 2002505307	W	20020219	(200216)		42
US 6605298	B1	20030812	(200355)		

APPLICATION DETAILS:

PATENT NO	KIND		APPLICATION	DATE
WO 9944642	A1		WO 1999-GB656	19990305
AU 9928455	A		AU 1999-28455	19990305
EP 1059941	A1		EP 1999-909085	19990305
			WO 1999-GB656	19990305
JP 2002505307	W		WO 1999-GB656	19990305
			JP 2000-534242	19990305
US 6605298	B1	Cont of	WO 1999-GB656	19990305
			US 2000-655476	20000905

FILING DETAILS:

PATENT NO	KIND		PATENT NO
AU 9928455	A	Based on	WO 9944642
EP 1059941	A1	Based on	WO 9944642
JP 2002505307	W	Based on	WO 9944642

PRIORITY APPLN. INFO: GB 1998-27835 19981217; GB 1998-4705 19980305
AN 1999-540749 [45] WPIDS

AB WO 9944642 A UPAB: 19991103
NOVELTY - Composition comprises:
(1) at least one micelle forming membrane lipid and
(2) at least one hydrophilic material to produce a liquid, gel or semi solid and which produces dispersed lipid aggregates upon contact or further dilution with an aqueous medium.
DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:
(A) a liquid **pharmaceutical composition** comprising a micelle forming lipid and a bilayer forming lipid, ethanol in an amount to mobilise the lipids and a polyol in an amount to maintain the lipids in solution at room temperature and
(B) a liquid **pharmaceutical composition** comprising a micelle forming lipid and a bilayer forming lipid, water to hydrate the lipid mixture and a biologically active compound.
USE - Used for delivering biologically active compounds to a living organism.
ADVANTAGE - The composition can mimic partially digested food mixture, allowing for higher absorption of 'problem' compounds compared to compositions only relying on diacyl phospholipids. The composition improves the bioavailability and consistency in absorption of lipophilic or hydrophilic compounds. The composition has good storage stability.
Cyclosporin A (10 pts.), commercial grade enzyme modified lecithin (55 pts.), ethanol (17.5 pts.), propylene glycol (12 pts.), glycerol (5 pts.) and water (5 pts.) were heated to 40 deg. C overnight.
The composition was administered to beagle dogs so that the amount of cyclosporin A administered was 100 mg in 2 x 500 mg gelatin capsules with 50 mg cyclosporin A in each capsule. Blood samples were taken after 1, 2, 4, 6, 8, 12 and 24 hours post administration and assayed for cyclosporin A.
Results showed that the composition had high bioavailability.
Dwg.0/1

L65 ANSWER 25 OF 27 USPATFULL on STN

ACCESSION NUMBER:	1998:78743 USPATFULL
TITLE:	Complex protein-walled microcapsules containing lipid-walled microcapsules and method for producing same
INVENTOR(S):	Chu, Fu-Lin E., Williamsburg, VA, United States Ozkizilcik, Sureyya, Baltimore, MD, United States
PATENT ASSIGNEE(S):	The Center for Innovative Technology, Herndon, VA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5776490		19980707	
APPLICATION INFO.:	US 1996-590701		19960126	(8)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Spear, James M.
LEGAL REPRESENTATIVE:	Whitham, Curtis & Whitham
NUMBER OF CLAIMS:	3
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT:	591

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Complex protein walled microcapsules (40) incorporate lipid-walled microcapsules (48) that include constituents to be retained in the presence of hydration such as water soluble vitamins and minerals. The protein walled microcapsules (40) are cross-linked, and include constituents (46) that are excluded from the lipid-walled microcapsules (48) and which are leachable from the protein walled microcapsules upon hydration. Other constituents (42 and 44), such as high molecular weight compounds and particulates may also be included in the protein walled microcapsules (40). Preferably, these other constituents (42 and 44) are chosen to be retained within the protein-walled microcapsules (40) upon

hydration. In a preferred embodiment, the complex protein-walled microcapsules are used as a fish larvae diet, wherein low molecular weight constituents, such as amino acids, that are incorporated into the protein-walled microcapsule but excluded from the lipid-walled microcapsule, are chosen for use as phagostimulants and attractants. They are leached out from the protein-walled microcapsule upon hydration. Nutrients such as vitamins and minerals are retained in the lipid-walled capsules of the complex protein-walled microcapsules. Larvae are stimulated from the leached phagostimulants and ingest the complex protein walled microcapsule as food, wherein the encapsulated water soluble vitamins and minerals, as well as the protein itself serve as nutrients for the larvae.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L65 ANSWER 26 OF 27 USPATFULL on STN

ACCESSION NUMBER:	92:14803 USPATFULL
TITLE:	Polymer-modified peptide drugs having enhanced biological and pharmacological activities
INVENTOR(S):	Braatz, James A., Beltsville, MD, United States Heifetz, Aaron H., Columbia, MD, United States
PATENT ASSIGNEE(S):	W. R. Grace & Co.-Conn., New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5091176		19920225
APPLICATION INFO.:	US 1990-510260		19900424 (7)

RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1988-266445, filed on 2 Nov 1988, now patented, Pat. No. US 4940737
DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Page, Thurman K.
ASSISTANT EXAMINER:	Kulkosky, Peter F.
LEGAL REPRESENTATIVE:	Appleby, Vanessa L., Krafte, Jill H., Trinker, Steven T.
NUMBER OF CLAIMS:	28
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT:	1029

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Biocompatible polymers derived from isocyanate-capped high molecular weight triols and higher polyols are covalently linked to drugs. These polymer-modified drugs have one or more of the following advantages over the unmodified drug: reduction of immunogenicity of the drug, increased circulating half-life of the drug due to longer residence time in circulation, ability to administer multiple drugs together, and enhanced potency of the drug.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L65 ANSWER 27 OF 27 RDISCLOSURE COPYRIGHT 2003 KENNETH MASON PUBL. on STN

ACCESSION NUMBER:	217038 RDISCLOSURE
TITLE:	Method for decomposition of polysac- charides, preferably plant cell wall polysac- c ha rides, by means of a carbohydrase
PATENT ASSIGNEE:	Anonymous
PATENT INFORMATION:	RD 217038 19820510
PRIORITY INFORMATION:	RD1982-217038 19820420
SOURCE:	Research Disclosure, 1982 05, 217 CODEN: RSDSBB; ISSN: 0374-4353
DOCUMENT TYPE:	Patent
GRAPHIC IMAGE SIZE:	47832; 48316; 43328; 55252; 62996; 44132; 9940

/ BINARY DATA / IMAGE001.TIF
/ BINARY DATA / IMAGE002.TIF
/ BINARY DATA / IMAGE003.TIF

```
/ BINARY DATA / IMAGE004.TIF
/ BINARY DATA / IMAGE005.TIF
/ BINARY DATA / IMAGE006.TIF
/ BINARY DATA / IMAGE007.TIF

START LOCAL KERMIT RECEIVE PROCESS

BINARY DATA HAVE BEEN DOWNLOADED TO MULTIPLES FILES 'IMAGEnnn.TIF'


=>
```